Navigation Links
Alseres Pharmaceuticals Expands Sites for the First Stage of the ALTROPANE(R) Phase III Clinical Trial Program
Date:4/17/2008

HOPKINTON, Mass., April 17 /PRNewswire-FirstCall/ -- Alseres Pharmaceuticals, Inc. (Nasdaq: ALSE) announced today that seven sites for the first stage of the ALTROPANE(R) Parkinson's or Essential Tremor - 2 (POET-2) Phase III clinical trial program are now open for patient enrollment. ALTROPANE molecular imaging agent is an investigational, diagnostic drug developed by Alseres to enable doctors to distinguish Parkinsonian Syndromes from non-Parkinsonian Syndromes in patients with tremor.

(Logo: http://www.newscom.com/cgi-bin/prnh/20070608/NEF043LOGO )

The POET-2 program is a two-part registration program, the first part of which is a clinical study designed to enroll up to 90 subjects with tremor in seven U.S. medical centers. The objective is to acquire the set of ALTROPANE images which will be used to train the expert readers, a customary practice for clinical trials of molecular imaging agents. The second part of the planned POET-2 program will involve two concurrent, replicate, multi-center Phase III trials using the optimized ALTROPANE imaging protocol Alseres developed for commercial use.

"Both the investigators and institutions participating in this study are among the best in the country," stated Mark Hurtt, M.D., Alseres Chief Medical Officer. "With their help, we are committed to advancing ALTROPANE toward regulatory approval and commercialization to aid in the diagnosis of Parkinson's Disease or Essential Tremor. If these trials are successful and the drug is approved, we believe that ALTROPANE could be a highly-selective central nervous system diagnostic molecular imaging agent -- and a valuable tool to help clinicians make
'/>"/>

SOURCE Alseres Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related medicine technology :

1. Alseres Pharmaceuticals Announces Expansion of the Cethrin(R) Acute Spinal Cord Injury (SCI) Phase I/IIA Clinical Trial
2. Alseres Pharmaceuticals Initiates the ALTROPANE(R) POET-2 Phase III Clinical Trial Program
3. Alseres Pharmaceuticals Concludes Enrollment in the Cethrin(R) Phase I/IIa Clinical Trial in Acute Spinal Cord Injury
4. Alseres Pharmaceuticals, Inc. to Address a Congressional Briefing on Paralysis Research and the Spinal Cord Injury Community at Working 2 Walk in Washington, DC, April 13-15, 2008
5. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
6. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
7. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
8. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
9. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
10. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
11. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/18/2008)... 2008 Faces of Influenza survey underscores that m...uenza; Mother and Gold Medalist Kristi Yamaguchi j...RNewswire/ -- While 78 percent of mothers in the U...tially life-threatening disease that can strike an...ll get vaccinated this season, according to a new ...
(Date:11/13/2008)...itional Supplements Prior to Surgery, ARLINGTON H...dentifying,malnutrition before surgery in massive ...significantly decrease surgical complications, acc...ost patient energy levels,according to a study in...Surgery(R), the official medical journal of the Am...
(Date:11/12/2008)...h James D. Watson, Marilyn & James Simons and,Sher..., Md., Nov. 12 J. Craig...aig Venter Institute (JCVI), was,awarded the Doubl...CSHL) on,November 6th at a gala event in New York ... along with Dr. James D.,Watson for making each of...
(Date:11/12/2008)... Study and New Data Suggesting Need for Improved ...l Meeting -, EXTON, Pa., Nov. 12 /PRNewswire-Firs... today announced the presentation of data from its...tudy Cinryze(TM) C1 inhibitor,therapy successfully...(HAE),attacks seen in the study through the date o...
Breaking Medicine Technology:Video: New Survey Finds Mothers See Influenza as a Serious Health Threat, but Often Don't Get Their Families Vaccinated 2Video: New Survey Finds Mothers See Influenza as a Serious Health Threat, but Often Don't Get Their Families Vaccinated 3Video: New Survey Finds Mothers See Influenza as a Serious Health Threat, but Often Don't Get Their Families Vaccinated 4Video: New Survey Finds Mothers See Influenza as a Serious Health Threat, but Often Don't Get Their Families Vaccinated 5Video: New Survey Finds Mothers See Influenza as a Serious Health Threat, but Often Don't Get Their Families Vaccinated 6Plastic Surgeons Warn of Malnutrition in Body Contouring Patients 2J. Craig Venter, Ph.D. Receives Double Helix Medal from Cold Spring Harbor Laboratory 2ViroPharma Announces Presentation of Cinryze(TM) Data in Acute Treatment of Hereditary Angioedema 2ViroPharma Announces Presentation of Cinryze(TM) Data in Acute Treatment of Hereditary Angioedema 3ViroPharma Announces Presentation of Cinryze(TM) Data in Acute Treatment of Hereditary Angioedema 4ViroPharma Announces Presentation of Cinryze(TM) Data in Acute Treatment of Hereditary Angioedema 5ViroPharma Announces Presentation of Cinryze(TM) Data in Acute Treatment of Hereditary Angioedema 6Raptor Pharmaceuticals Corp Initiates Phase IIa Clinical Study for Convivia 28TM 29 1856 1Raptor Pharmaceuticals Corp Initiates Phase IIa Clinical Study for Convivia 28TM 29 1856 2Raptor Pharmaceuticals Corp Initiates Phase IIa Clinical Study for Convivia 28TM 29 1856 3Raptor Pharmaceuticals Corp Initiates Phase IIa Clinical Study for Convivia 28TM 29 1856 4Raptor Pharmaceuticals Corp Initiates Phase IIa Clinical Study for Convivia 28TM 29 1856 55th Annual World Health Care Congress Kicks off April 21 With Obama Clinton McCain Health Care Policy Advisor Presidential Health Care Agenda Forum 17263 15th Annual World Health Care Congress Kicks off April 21 With Obama Clinton McCain Health Care Policy Advisor Presidential Health Care Agenda Forum 17263 2 C O R R E C T I O N Mobidiag Ltd 4718 1 C O R R E C T I O N Mobidiag Ltd 4718 2Vernalis and Paul Capital Healthcare Sign euro 18 4 Million Financing Agreement 4717 1Vernalis and Paul Capital Healthcare Sign euro 18 4 Million Financing Agreement 4717 2Vernalis and Paul Capital Healthcare Sign euro 18 4 Million Financing Agreement 4717 3
(Date:11/21/2008)...about future antibiotic resistance from widespread...ws) -- People with moderate to severe chronic obst...duce the frequency of exacerbations through a regu... says. , The study, published in the first iss...atory and Critical Care Medicine , found that twic...
(Date:11/21/2008)...wswire-USNewswire/ -- New research at West Virgin...pitless tobacco product aimed at young adults is c... Reynolds, Camel Snus - touted as a socially accep...ngly high levels of nicotine. , , "Camel Sn...oducts," said Bruce Adkins of the state Division o...
(Date:11/21/2008)...- The general membership of the Medical,Advertisi...als at their Annual,Awards Dinner to be held Febr...Lifetime Achievement Award will also be given. , ...ing Hall of Fame are: , Ronald Pantello, who be...n,at Sudler & Hennessey. In 1980 he left Sudl...
(Date:11/21/2008)... increases production of neural stem cells , ...riments in mice, exercise appears to reverse the d...ly seen with aging, Taiwanese researchers report. ...ility to stave off aging appears to be due to exer...essential for the production of new brain cells. ...
Breaking Medicine News(10 mins):Health News:Long-Term Erythromycin Cut COPD Complications 2Health News:Experts Say New Tobacco Product Targets Young Adults 2Health News:Experts Say New Tobacco Product Targets Young Adults 3Health News:Ronald Pantello, Harry Sweeney, and David Wood Voted Into Medical Advertising Hall of Fame. 2Health News:Ronald Pantello, Harry Sweeney, and David Wood Voted Into Medical Advertising Hall of Fame. 3Health News:Exercise Keeps the Brain Young 2
...er Hewlett Professor of Internal Medicine at the U...e saying// that the qualities of service provided ... compromised. The study was mainly conducted to su... work hours implemented since 2003. The findings w...
...al Economy Research Institute at the University of...anies that are responsible for air pollution//. Th...rporate companies are listed as an important sourc... of hundreds of chemicals from industrial faciliti...
...as legalized abortion. But the rivals of the new S...eme Court. The new law is on its way to go// in to...d to decide the fate of the law. The opponents of ... 19 on petitions designed to put the law on the No...
...on of common genes linked to cancer is expected to...al Cancer Institute report that huge resources// a... genetic variants that would increase the suscepti... that there are a number of problems when doing su...
Other Medicine News:
Infant Nebulizer Kit W/Misty-Nebulizer 30/CS CE Mark Only
...ted Clinical Applications:, ,Cool Aerosol Therapy...th open system devices such as aerosol masks, face...de only limited FIO2 and limited flow. The design ...dental dilution with room air or high FIO2 due to ...
...w PARI TREK™ Compact Compressor is for activ...ts anywhere and everywhere. The compressor is smal...ower source optionsworldwide AC compatibility (100...rmit patients the freedom to take aerosol treatmen...
...ucing Quieter Compressed Air., ,Allied Healthcare...so much quieter than other air compressors that yo... too. The PCS 414 features a durable, mar-resistan..., the unit weighs only 26.5 pounds. The PCS 414 ha...
Medicine Products: